Testing memantine added to dopamine-targeting treatment for early psychosis
Treatments studied
Part of Mental health clinical trials.
This Phase 1 study tests whether adding memantine can improve “negative symptoms” (like low motivation, reduced emotional expression) in people having their first episode of psychosis. It’s designed to understand safety and early effects when dopamine-related treatment is adjusted.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have your first episode of psychosis and meet diagnosis criteria confirmed by an interview
- You are 18 to 45 years old
- For patients: you have not taken antipsychotic medicine for at least 30 days before joining (and no long prior use as defined by the study)
- For patients: you must not have taken antidepressant medicine in the last 7 days
- You can’t be pregnant, and you must use reliable contraception during the study (if you could become pregnant)
- You should not have certain health/safety issues (like a pacemaker or metal implants, or significant head injury/unconsciousness)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a cognitive training program can help young adults with recent psychosis improve their thinking and memory skills. It involves brain scans and cognitive exercises.
This study tests if adding a CBD medication to your current antipsychotic can improve symptoms in people with schizophrenia or related disorders who started treatment recently but aren't fully better yet.
This study explores how thinking and memory work in people who have experienced early psychosis. It involves computer tasks, brain scans, and a type of brain stimulation to better understand cognition. The study has two parts: one for people currently in early psychosis and one for people who have had psychosis at any point.
This Phase 2 study tests an NMDA-enhancer medicine to see if it can help people who are in the early “prodromal” stage—when symptoms are starting but full schizophrenia is not diagnosed yet. It aims to reduce or prevent worsening symptoms over the study period.
This study tests whether a medication that boosts brain NMDA receptors can improve negative symptoms in schizophrenia, and looks at differences between men and women. It is for people with stable schizophrenia who still have mostly flat mood or low motivation.
This study tests a new treatment that may help with thinking and memory problems in people with schizophrenia. It is for people whose schizophrenia symptoms are stable and who are already on a steady medication.
Hear when a new Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.